AHA 2017 The REAL-CAD trial demonstrated that CV events and overall mortality were reduced by pitavastatin compared to low-intensity statin treatment in Japanese stable CAD patients.
AHA 2017 An analysis of the EXSCEL trial examined whether risk at baseline predicted the effect of exenatide on mortality and MACE.
AHA 2017 A sub-analysis of the EMPA-REG OUTCOME examined whether the benefits of empaglifozin are preserved in diabetic patients with and without PAD.
AHA 2017 In the SPRINT tiral, BP measurement was no always conducted i nthe absence of a physician or nurse. A posthoc analysis evaluated whether this affected the results.
AHA 2017 Comparison of two triggers for RBC transfusion showed that a restrictive strategy was non-inferior to a liberal transfusion approach in moderate to high risk patients.
AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but respons to treatment did.
AHA 2017 The new guidelines now define hypertension as >130/80 mmHg, emphasize the need for lifestyle changes and specify details of accurate BP measurement methods.
AHA 2017 A lot of variation in BP measurement methods were seen in SPRINT, despite the protocol, but in 3/4 of sites patients were alone at least at some point during the BP reading.
AHA 2017 Paul Whelton, chair of the 2017 Hypertension Practice Guidelines, summarises the major changes as compared with the previous guideline.
AHA 2017 A post-hoc survey of the SPRINT examined whether the presence or absence of physician or nursing during the BP measurement changed the treatment effect.
AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.
AHA 2017 Gastric bypass in obese hypertensives (BMI 30-39.9) led to stable BP and reduction of medication need in the majority of patients, and about half showed remission after 1 year.